Vyleesi Liver Function Impact: What Bremelanotide Does to Your Liver

What Is Bremelanotide and Why Does the Liver Question Matter?

Bremelanotide is a melanocortin receptor agonist approved by the FDA in June 2019 for the treatment of HSDD in premenopausal women. It acts primarily at central MC1R and MC4R receptors, modulating pathways tied to sexual desire rather than peripheral hormone levels. Any drug processed by the body eventually intersects with hepatic physiology, and prescribers routinely ask whether bremelanotide poses a meaningful liver risk.

The short answer: the liver safety profile from the key RECONNECT program is reassuring, but not completely silent. A subset of participants showed transient transaminase elevations. Understanding the magnitude, reversibility, and clinical significance of those elevations is what this article covers.

How the FDA Evaluated Liver Safety Before Approval

Before approving Vyleesi, the FDA reviewed the full RECONNECT safety dataset. The agency's drug approval package, available through FDA accessdata, documents a thorough hepatic assessment. No cases of acute hepatic failure, jaundice, or clinically significant hyperbilirubinemia were identified in the pre-approval database [1].

The FDA label does require that prescribers exercise caution in patients with severe hepatic impairment (Child-Pugh Class C), largely because pharmacokinetic data in this subgroup are limited rather than because of observed liver toxicity signals [1].

Bremelanotide Metabolism: Why the Liver Is Involved

Bremelanotide undergoes hydrolysis of its peptide bonds, primarily in plasma and tissues, rather than undergoing extensive first-pass hepatic metabolism via cytochrome P450 enzymes [2]. This metabolic route means the liver sees far less drug burden than it does with small-molecule drugs that are CYP3A4 or CYP2D6 substrates.

Secondary metabolites are renally and fecally excreted [2]. Because hepatic CYP involvement is minimal, the theoretical risk of CYP-mediated drug-drug interactions involving liver enzymes is low. Nonetheless, the liver does participate in peptide catabolism broadly, which is why pharmacokinetic studies in impaired populations remain clinically relevant.

RECONNECT Trial: Liver Function Data in Detail

The RECONNECT program comprised two parallel, randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling a combined 1,267 premenopausal women with HSDD. Results were published in Obstetrics and Gynecology in 2019 [3].

Primary Efficacy Outcomes

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Both trials met statistical significance for both endpoints [3]. Because this article focuses on liver impact, efficacy is summarized only to establish the trial's regulatory weight.

Transaminase Findings in RECONNECT

In the pooled safety population, elevated ALT or AST values were uncommon and generally grade 1 (less than 3x the upper limit of normal, ULN) by CTCAE criteria [3]. No participant in the key trials met Hy's Law criteria, the combined threshold of ALT or AST greater than 3x ULN plus total bilirubin greater than 2x ULN plus no competing explanation, which the FDA uses as a signal of serious DILI risk [4].

The FDA guidance on drug-induced liver injury, developed in collaboration with the National Institutes of Health, specifies that Hy's Law cases in clinical trials are the strongest predictor of post-marketing hepatotoxicity [4]. The absence of any Hy's Law cases across 1,267 participants in RECONNECT is clinically meaningful.

Grade 1 transaminase elevations that did appear resolved without dose interruption in the majority of affected participants. The trial did not mandate liver function testing at fixed intervals, which reflects the low a priori hepatotoxicity concern the FDA and investigators had going into the studies [3].

Comparison With the Flibanserin (Addyi) Liver Profile

Flibanserin, the only other FDA-approved HSDD therapy, is a CYP3A4 substrate and carries a black-box warning against use with CYP3A4 inhibitors partly because of cardiovascular interactions, but also because of pharmacokinetic exposure amplification that could affect hepatic clearance [5]. Bremelanotide's predominantly non-CYP metabolism means it does not share this interaction profile [2]. Prescribers switching patients from flibanserin to bremelanotide should recognize this mechanistic difference when evaluating liver-related risk.

FDA Label Language on Hepatic Impairment

The current Vyleesi prescribing information categorizes patients by Child-Pugh class [1]:

• Mild impairment (Child-Pugh A): No dose adjustment required.
• Moderate impairment (Child-Pugh B): No dose adjustment required; use with standard clinical judgment.
• Severe impairment (Child-Pugh C): Use with caution. Pharmacokinetic data are insufficient to establish safety in this group.

The label language reflects a data gap more than an observed danger signal. The FDA did not require a post-marketing liver safety study as a condition of approval [1], which is a meaningful regulatory signal in itself.

What "Use With Caution" Means Clinically

"Use with caution" in the context of severe hepatic impairment is FDA label language indicating that the prescriber should weigh individual risk against benefit without specific dosing guidance to fall back on [6]. For the majority of bremelanotide prescriptions, which go to otherwise healthy premenopausal women, Child-Pugh C is essentially irrelevant. Cirrhosis and end-stage liver disease are rare in this demographic.

Prescribers seeing patients with moderate liver disease (Child-Pugh B) may choose to order a baseline ALT, AST, and total bilirubin panel before starting bremelanotide, then repeat at 4 to 8 weeks, as a conservative monitoring practice. This is not FDA-mandated but aligns with general principles articulated in the FDA's 2009 guidance on pharmacokinetics in patients with impaired hepatic function [6].

Mechanistic Pathways: How Bremelanotide Could Theoretically Affect the Liver

Melanocortin Receptors in Hepatic Tissue

MC1R and MC4R are expressed not only in the central nervous system but in peripheral tissues including the liver [7]. Pre-clinical research published in PubMed-indexed journals has shown that melanocortin signaling in hepatic stellate cells may modulate fibrogenic and inflammatory pathways [7]. At therapeutic doses of 1.75 mg administered subcutaneously, systemic bremelanotide concentrations are unlikely to produce pharmacologically significant peripheral MC receptor activation beyond the intended CNS target, but the biology is worth acknowledging.

Inflammatory Cytokine Modulation

MC4R agonism has been associated with downregulation of pro-inflammatory cytokines including TNF-alpha and IL-6 in rodent models [8]. These same cytokines are central to non-alcoholic steatohepatitis (NASH) progression. Whether therapeutic-dose bremelanotide could have a minor hepatoprotective or neutral effect in humans with early liver inflammation remains an open question. No human clinical data currently address this [8].

Nausea, Vomiting, and Secondary Hepatic Stress

Nausea is the most common adverse effect of bremelanotide, reported in approximately 40% of participants in RECONNECT [3]. Severe, prolonged vomiting can transiently raise liver enzymes via mechanisms including dehydration-related hepatic hypoperfusion. In RECONNECT, nausea was generally mild to moderate, resolved within 12 hours, and did not trigger significant transaminase spikes in the clinical dataset [3]. Prescribers should still note that patients with severe, protracted nausea on bremelanotide represent a subgroup where monitoring ALT makes clinical sense.

Post-Marketing Liver Safety: What the Real-World Data Show

The FDA's MedWatch adverse event reporting system (FAERS) has received post-marketing reports for bremelanotide since its June 2019 approval [9]. Signals related to hepatotoxicity remain rare in FAERS, and no label update adding liver-specific warnings has been issued as of mid-2025 [1].

The American Association for the Study of Liver Diseases (AASLD) LiverTox database, maintained by the NIH, provides a probability-weighted assessment of drug hepatotoxicity likelihood [10]. LiverTox classifies bremelanotide as a drug with insufficient evidence to establish hepatotoxic potential, reflecting the absence of consistent clinical or post-marketing liver injury signals [10].

Interpreting Low FAERS Signal Appropriately

FAERS data are subject to under-reporting bias. A low hepatotoxicity signal in FAERS does not guarantee zero risk; it indicates that spontaneous reports have not reached a threshold that triggered FDA regulatory action [9]. For bremelanotide, the biological plausibility of hepatotoxicity is also low, given its peptide hydrolysis metabolism and absence of Hy's Law cases in 1,267 trial participants, which together support genuine low-risk classification rather than under-detection [3,4].

Monitoring Recommendations for Clinical Practice

No professional society has issued bremelanotide-specific liver monitoring guidelines as of 2025. The Endocrine Society's clinical practice guidelines on female sexual dysfunction address treatment choices but do not mandate LFT monitoring for bremelanotide users [11]. The American College of Obstetricians and Gynecologists (ACOG) similarly does not require baseline or interval liver testing before prescribing Vyleesi in women with intact hepatic function [12].

A Practical Monitoring Framework

For most premenopausal women starting bremelanotide:

• No liver disease history: Baseline LFTs are not required per FDA label or ACOG guidance. Order them only if clinical context warrants (e.g., heavy alcohol use, obesity with suspected metabolic-associated steatotic liver disease).
• Mild-to-moderate liver disease (Child-Pugh A or B): Obtain baseline ALT, AST, and total bilirubin. Consider a repeat panel at 4 to 8 weeks.
• Severe liver disease (Child-Pugh C): Avoid bremelanotide unless a documented risk-benefit discussion supports use. Consult hepatology.
• Persistent severe nausea/vomiting on bremelanotide: Check ALT and AST at the next clinical visit to rule out secondary transaminase elevation.

Drug Interactions With Hepatic Relevance

Because bremelanotide is not a CYP3A4 substrate or inhibitor, co-administration with common CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) or inducers (rifampin, carbamazepine) does not carry the same pharmacokinetic liver-burden concern as with flibanserin [5]. The FDA label notes that bremelanotide may slow gastric emptying, which could reduce absorption of orally administered drugs metabolized hepatically, a relevant consideration when co-prescribing [1]. Naltrexone is specifically flagged in the label because bremelanotide slows naltrexone absorption significantly [1].

Special Populations and Liver Considerations

Women With Metabolic-Associated Steatotic Liver Disease

Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) affects approximately 25% of the global adult population according to a 2022 meta-analysis in the Journal of Hepatology [13]. HSDD is also prevalent in women with obesity and metabolic syndrome, meaning clinicians will encounter this overlap. No dedicated MASLD subgroup analysis exists in the RECONNECT dataset. Given bremelanotide's low CYP burden, its hepatic risk in early MASLD (Child-Pugh A) is expected to be similar to the general trial population, but this remains an evidence gap.

Alcohol Use and the Liver

Alcohol-related liver disease exists on a spectrum from steatosis through cirrhosis. Women with heavy alcohol use were not systematically excluded from RECONNECT, but Child-Pugh scoring would capture those with significant fibrosis or cirrhosis [3]. For women with active heavy alcohol use and HSDD, addressing alcohol use disorder as a first step is clinically appropriate before initiating any pharmacotherapy for HSDD, given the established bidirectional relationship between alcohol use disorder and sexual dysfunction documented in General Hospital Psychiatry [14].

Hepatitis B and C Co-Infection

Chronic viral hepatitis (HBV or HCV) can produce elevated baseline transaminases that complicate monitoring. No published data address bremelanotide specifically in HBV or HCV-infected populations. Prescribers should document baseline liver enzyme values in these patients and maintain a low threshold for specialist co-management. The 2018 AASLD HCV guidance supports treating HCV prior to adding non-essential pharmacotherapy when liver fibrosis is advanced [15].

Clinical Pearls for the Prescribing Physician

The hepatic safety profile of bremelanotide compares favorably with many other chronic medications commonly prescribed to premenopausal women. Combined oral contraceptives carry well-documented risks of cholestasis and hepatic adenoma with long-term use [16]. Non-steroidal anti-inflammatory drugs (NSAIDs) used chronically produce idiosyncratic hepatotoxicity at low but real rates [17]. Bremelanotide, used on-demand at most 8 times per month, presents far less cumulative hepatic exposure than a daily medication.

The as-needed dosing schedule is a genuine liver safety advantage. Cumulative drug exposure drives dose-dependent hepatotoxicity for many agents. Because bremelanotide is taken only before anticipated sexual activity rather than daily, total monthly systemic exposure is substantially lower than a daily dosing regimen at the same per-dose amount [1,3].

Prescribers should document in the medical record that they have reviewed the patient's liver history before initiating Vyleesi, even when no formal monitoring is required. This documentation supports shared decision-making and demonstrates standard-of-care adherence consistent with FDA labeling [1].

The Endocrine Society's 2019 position on female sexual dysfunction notes: "Pharmacological treatment should be individualized based on the patient's specific symptom profile, comorbidities, and medication safety data" [11]. For a premenopausal woman with HSDD and no liver disease, bremelanotide's liver safety data support proceeding without mandatory hepatic monitoring.